Blood-based biomarkers for Alzheimer disease have advanced rapidly, demonstrating strong diagnostic performance and associations with clinical progression. With recommended sensitivity and specificity thresholds now established, this Clinical Outlook considers the readiness of the tests for clinical implementation.
Access to this article via Institution of Civil Engineers Library is not available. Pahlke, S.
et al. Blood-based biomarkers for detecting Alzheimer’s disease pathology in cognitively impaired individuals within specialized care settings: a systematic review and meta-analysis.
Alzheimers Dement. 21 , e70828 (2025).
Jack, C. R.
Jr et al. Revised criteria for the diagnosis and staging of Alzheimer’s disease.
Nat. Med.
30 , 2121–2124 (2024). Honey, M.
I. J.
et al. Individualized prediction of clinical progression to dementia using plasma biomarkers in non-demented elderly.
Alzheimers Res. Ther.
18 , 4 (2025). Trieu, C.
et al. Longitudinal blood-based biomarkers and clinical progression in subjective cognitive decline.
JAMA Netw. Open 8 , e2545862 (2025).
Mielke, M. M.
et al. Recommendations for clinical implementation of blood-based biomarkers for Alzheimer’s disease.
Alzheimers Dement. 20 , 8216–8224 (2024).
Hansson, O. et al.
Nature Reviews Neurology published a clinical update in Neurology on 06 May 2026.
The item focuses on Plasma biomarkers for Alzheimer disease: the road from laboratory results to clinical practice.
Review the original article for the full source wording and details.